Symbiotec Pharmalab Files DRHP for Rs 2,180 Cr IPO, Backed by Rosewood, Motilal Oswal

• Symbiotec Pharmalab, backed by Rosewood Investments and Motilal Oswal, filed DRHP with SEBI on Dec 19 for a Rs 2,180 crore IPO.
• The IPO includes a Rs 150 crore fresh issue and a Rs 2,030 crore offer-for-sale by existing shareholders like Rosewood and India Business Excellence Fund – III.
• Rs 112.5 crore from fresh issue will repay debt; remaining for general corporate purposes. OFS funds go to selling shareholders.
• The company claims global leadership in corticosteroid (36.2% market share) and steroidal-hormone (44.2% market share) APIs.
• Reported FY24-25 revenue of Rs 751.6 crore (up 5%) and profit of Rs 96.8 crore (down 3.3%).

Why It Matters: Symbiotec Pharmalab seeks Rs 2,180 Cr through IPO, leveraging its API market leadership and investor backing.